Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.49 |
| ▸ | KLK7 | P49862 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.44 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | FYN | P06241 | 5/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23768212 | 0.82 | MKNK1 (0.46) | MKNK1KLK7DYRK1ASSTR4PRMT5 | |
| SCHEMBL21016720 | 0.81 | MKNK1 (0.45) | MKNK1KLK7DYRK1ASSTR4PRMT5 | |
| SCHEMBL16324975 | 0.77 | MKNK1 (0.45) | MKNK1KLK7DYRK1ASSTR4PRMT5 | |
| SCHEMBL84692 | 0.75 | MKNK1 (0.53) | MKNK1KLK7DYRK1ASSTR4PRMT5 | |
| SCHEMBL22891212 | 0.73 | HSD11B1 (0.51) | MKNK1KLK7DYRK1ASSTR4HSD11B1 | |
| SCHEMBL21016719 | 0.72 | SSTR4 (0.38) | MKNK1KLK7DYRK1ASSTR4PRMT5 | |
| SCHEMBL14867362 | 0.71 | GRM4 (0.47) | KLK7 | |
| SCHEMBL22510132 | 0.71 | MKNK1 (0.53) | MKNK1KLK7DYRK1ASSTR4PRMT5 | |
| SCHEMBL2392859 | 0.71 | MKNK1 (0.53) | MKNK1KLK7DYRK1ASSTR4PRMT5 | |
| SCHEMBL477032 | 0.71 | MKNK1 (0.53) | MKNK1KLK7DYRK1ASSTR4PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024124002-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | THIRD HARMONIC BIO, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| CN-116888126-A | Compound of casein kinase inhibitor | 北京原基华毅生物科技有限公司 | 2023-10-13 | — | — | CN | disclosed |
| US-20230250060-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
| US-20170145009-A1 | HETEROCYCLIC COMPOUNDS THAT INHIBIT THE KINASE ACTIVITY OF MNK USEFUL FOR TREATING VARIOUS CANCERS | EFFECTOR THERAPEUTICS, INC. | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250060-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | MKNK1 1329/4885KLK7 2706/4885DYRK1A 4056/4885 |
| US-20170145009-A1 | HETEROCYCLIC COMPOUNDS THAT INHIBIT THE KINASE ACTIVITY OF MNK USEFUL FOR TREATING VARIOUS CANCERS | MAP3K9, MAP3K19, MAP3K20 | MKNK1 78/4885KLK7 632/4885DYRK1A 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.